Certara, Inc. $CERT Shares Acquired by London Co. of Virginia

London Co. of Virginia lifted its holdings in Certara, Inc. (NASDAQ:CERT) by 5.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,554,991 shares of the company’s stock after buying an additional 82,283 shares during the period. London Co. of Virginia owned approximately 0.98% of Certara worth $19,002,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CERT. Wasatch Advisors LP raised its holdings in Certara by 45.7% in the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after acquiring an additional 4,244,230 shares during the last quarter. Deerfield Management Company L.P. boosted its holdings in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after purchasing an additional 2,813,438 shares during the last quarter. Marshall Wace LLP grew its position in shares of Certara by 1,430.6% in the second quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock valued at $17,694,000 after purchasing an additional 1,413,538 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Certara by 27.1% in the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH acquired a new stake in shares of Certara in the third quarter valued at approximately $11,899,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Trading Down 2.4%

Shares of Certara stock opened at $6.49 on Tuesday. The stock has a 50 day moving average of $7.92 and a 200 day moving average of $9.57. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -649.00 and a beta of 1.50. Certara, Inc. has a fifty-two week low of $6.04 and a fifty-two week high of $15.38.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. Certara’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CERT. KeyCorp reduced their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Finally, Morgan Stanley dropped their price objective on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.10.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.